Alpha Cognition Inc
ACOG
Rank in Stocks
#19988
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Share Price
$8.85
Market Cap
$137.45M
Change (1 day)
4.12%
Change (1 year)
75.94%
Country
US
Trade Alpha Cognition Inc (ACOG)
Category
Healthcare
Revenue for Alpha Cognition Inc (ACOG)
Revenue in Jun 2026 TTM: $6.09M
According to Alpha Cognition Inc latest financial reports the company's current revenue (TTM) is $6.09M. In 2022 the company made a revenue of 0.00 equal to the revenue in the year 2021 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Alpha Cognition Inc from 2018 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $6.09M | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 207,094.38% |
US
|
|
| $2.23B | 36,466.71% |
US
|
|
| $15.74B | 258,301.35% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 98,723.45% |
NL
|
